Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
April 2018
-
Media ReleaseNovartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalaprilPost-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
-
DNA-encoded molecules provide a new edge in cancer drug hunts
Novartis researchers are using new technologies, such as DNA-encoded libraries, to find new ways to treat disease.
March 2018
-
Media ReleaseNovartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVOBasel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
-
Media ReleaseAveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Key ReleaseNovartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic prioritiesPrice reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
-
Key ReleaseNovartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrierenPreis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Malaria is still disrupting lives, despite progress
The disease hobbles families and economies.
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MSEXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
-
Media ReleaseNovartis drug Tasigna® approved by FDA to treat children with rare form of leukemiaTasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
-
Building “boot camps” for immune cells near tumors
Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.
-
Media ReleaseNovartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapiesCollaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
Pagination
- ‹ Previous page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- …
- 152
- › Next page